Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A series of combretastatin A-4 analogs derived from the ATP competitive, VEGF receptor tyrosine kinase inhibitor, SU5416 were synthesized. The cytotoxic effects of the analogs were evaluated against PC-3 and MDA-MB-231 cancer cell lines, as well as their abilities to inhibit tubulin polymerization. Results are compared to those of compound 1, our lead compound previously reported.

Original publication

DOI

10.1016/j.bmc.2006.06.017

Type

Journal article

Journal

Bioorg Med Chem

Publication Date

01/10/2006

Volume

14

Pages

6492 - 6501

Keywords

Antineoplastic Agents, Phytogenic, Cell Cycle, Cell Line, Tumor, Cell Proliferation, Chromatography, High Pressure Liquid, DNA, Neoplasm, Drug Screening Assays, Antitumor, Female, Humans, Indoles, Isomerism, Magnetic Resonance Spectroscopy, Molecular Conformation, Podophyllotoxin, Pyrroles, Stilbenes, Structure-Activity Relationship, Tubulin